Neuren Names Horrigan VP Of Clinical Development And Medical Affairs

8/10/2012 6:08 AM ET

Neuren Pharmaceuticals Ltd. (NEU.AX), a company that developes new therapies for brain injury, cancer etc., Friday announced that Joseph Horrigan has joined the company as the Vice President of clinical development and medical affairs.

Horrigan recently worked at Autism Speaks as Assistant Vice President and Head of Medical Research. In that role, he oversaw the organization's medical research and training programs including consulting with academic and industry groups on clinical trial design and endpoints in neurodevelopmental disorders.

From 2002 until he joined Autism Speaks, Horrigan coordinated paediatric drug development in the Neurosciences Medicines Development Center at GlaxoSmithKline.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

<<Previous 74 Articles

Editors Pick

Fed Minutes Show Some Members Want To Scale Back QE3 This Summer

Some members of the Federal Reserve favor scaling back the central bank's $85 billion a month asset purchase program this summer as long as the economy continues to improve, according the the minutes of the Fed's April 30-May 1 meeting. "A number of participants expressed willingness to adjust the...

Stocks Come Under Pressure Amid Worries About Fed - U.S. Commentary

After moving mostly higher over the course of morning trading on Wednesday, stocks have shown a notable move back to the downside in the afternoon. The major averages have pulled back well off their highs for the session and into negative territory. The major averages have moved roughly sideways in recent trading, lingering near their new lows for the session.

Immigration Reform Bill Clears Senate Judiciary Committee

Comprehensive immigration reform legislation took a step toward approval on Tuesday, as the members of the Senate Judiciary Committee voted to send the bill to the Senate floor. The Senate Judiciary Committee voted 13 to 5 in favor of the bill, with three Republicans joining with the panel's ten Democrats in voting to support the legislation.